Stock Research for CYTK

CYTK

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

CYTK Stock Chart & Research Data

The CYTK chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the CYTK chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


CYTK Due diligence Resources & Stock Charts

The CYTK stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View CYTK Detailed Price Forecast - CNN Money CNN View CYTK Detailed Summary - Google Finance
Yahoo View CYTK Detailed Summary - Yahoo! Finance Zacks View CYTK Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View CYTK Trends & Analysis - Trade-Ideas Barrons View CYTK Major Holders - Barrons
NASDAQ View CYTK Call Transcripts - NASDAQ Seeking View CYTK Breaking News & Analysis - Seeking Alpha
Spotlight View CYTK Annual Report - CompanySpotlight.com OTC Report View CYTK OTC Short Report - OTCShortReport.com
TradeKing View CYTK Fundamentals - TradeKing Charts View CYTK SEC Filings - Bar Chart
WSJ View Historical Prices for CYTK - The WSJ Morningstar View Performance/Total Return for CYTK - Morningstar
MarketWatch View the Analyst Estimates for CYTK - MarketWatch CNBC View the Earnings History for CYTK - CNBC
StockMarketWatch View the CYTK Earnings - StockMarketWatch MacroAxis View CYTK Buy or Sell Recommendations - MacroAxis
Bullish View the CYTK Bullish Patterns - American Bulls Short Pains View CYTK Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View CYTK Stock Mentions - StockTwits PennyStocks View CYTK Stock Mentions - PennyStockTweets
Twitter View CYTK Stock Mentions - Twitter Invest Hub View CYTK Investment Forum News - Investor Hub
Yahoo View CYTK Stock Mentions - Yahoo! Message Board Seeking Alpha View CYTK Stock Mentions - Seeking Alpha






Financial & Transaction Holdings

SECform4 View Insider Transactions for CYTK - SECform4.com Insider Cow View Insider Transactions for CYTK - Insider Cow
CNBC View CYTK Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for CYTK - OTC Markets
Yahoo View Insider Transactions for CYTK - Yahoo! Finance NASDAQ View Institutional Holdings for CYTK - NASDAQ


Stock Charts

FinViz View CYTK Stock Insight & Charts - FinViz.com StockCharts View CYTK Investment Charts - StockCharts.com
BarChart View CYTK Stock Overview & Charts - BarChart Trading View View CYTK User Generated Charts - Trading View


Latest Financial News for CYTK

Cytokinetics Announces Data From Phase 2 Clinical Study of Reldesemtiv in Patients With Spinal Muscular Atrophy Presented at the 2018 Annual Cure SMA Conference
Posted on Saturday June 16, 2018

Cytokinetics, Incorporated (CYTK) today announced data from the Phase 2 clinical study of reldesemtiv in patients with spinal muscular atrophy (SMA) were presented in an oral presentation by John W. Day, M.D., Ph.D., Professor of Neurology and Pediatrics (Genetics), Stanford University, at the 2018 Annual Cure SMA Conference in Dallas. In collaboration with Astellas, Cytokinetics is developing reldesemtiv as a potential treatment for people with SMA and certain other debilitating diseases and conditions associated with skeletal muscle weakness and/or fatigue. The study, which examined two dose levels of reldesemtiv, 150 mg or 450 mg twice daily, demonstrated dose-dependent increases in 6MWD in ambulatory patients as measured at both post-baseline time points, week four and week eight.


Cytokinetics to Present at the JMP Securities Life Sciences Conference
Posted on Wednesday June 13, 2018

Cytokinetics, Inc. (CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the JMP Securities Life Sciences Conference on Wednesday, June 20, 2018 at 11:00 AM EDT at the St. Regis Hotel in New York. The webcast replay of the presentation will be archived on the Presentations page within the Investors & Media section of Cytokinetics' website for 90 days following the conclusion of the event. Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining.


3 Biotechs with Upcoming Data to Watch
Posted on Monday June 11, 2018

Cytokinetics (NASDASQ:CYTK) looks to turn around their fortunes following last year’s unsuccessful readout of Tirasemtiv in ALS. The company’s follow on asset Reldesemtiv, is built on the same mechanism but looks to resolve the dropout issue. Further, the drug seems to be more potent than its predecessor, which may help amplify the signal we saw in respiratory function.


Cytokinetics Announces Data From Phase 2 Clinical Study of Reldesemtiv in Patients With Spinal Muscular Atrophy to be Presented at the 2018 Annual Cure SMA Conference on June 16, 2018
Posted on Friday June 08, 2018

Cytokinetics, Incorporated (CYTK) today announced that data from the Phase 2 clinical study of reldesemtiv in patients with spinal muscular atrophy (SMA) will be presented in an oral presentation at the 2018 Annual Cure SMA Conference in Dallas on June 16, 2018. Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining.


Enter a stock symbol to view the stock details.